Work

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7519

Authors: Jacob Drobnyk Soumerai, John M. Pagel, Deepa Jagadeesh, Huda S. Salman, Vaishalee Padgaonkar Kenkre, Adam Steven Asch, Anastasios Stathis, Nishitha M. Reddy, Alexia Iasonos, Richard Ghalie, Andrew David Zelenetz

Institutions: Massachusetts General Hospital, Cleveland Clinic, Stony Brook University, University of Wisconsin–Madison, OU Health Stephenson Cancer Center, Istituto Oncologico della Svizzera Italiana, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Memorial Sloan Kettering Cancer Center, MEI Pharma (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890636397

Cites:

Cited by: 18

Related to: 10